Loading...

EL.En. S.p.A.

ELEAFPNK
Healthcare
Medical - Devices
$12.52
$0.00(0.00%)

EL.En. S.p.A. (ELEAF) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for EL.En. S.p.A. (ELEAF), covering cash flow, earnings, and balance sheets.

Revenue Growth
-18.26%
18.26%
Operating Income Growth
7.66%
7.66%
Net Income Growth
6.99%
6.99%
Operating Cash Flow Growth
579.50%
579.50%
Operating Margin
16.55%
16.55%
Gross Margin
42.96%
42.96%
Net Profit Margin
7.65%
7.65%
ROE
14.66%
14.66%
ROIC
0.00%

EL.En. S.p.A. (ELEAF) Income Statement & Financial Overview

View the income breakdown for EL.En. S.p.A. ELEAF across both annual and quarterly reports.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$99.62M$153.26M$159.86M$153.10M
Cost of Revenue$43.80M$93.23M$99.31M$90.70M
Gross Profit$55.82M$60.04M$60.55M$62.40M
Gross Profit Ratio$0.56$0.39$0.38$0.41
R&D Expenses$0.00$0.00$0.00$5.24M
SG&A Expenses$0.00$0.00$42.97M$43.18M
Operating Expenses$28.39M$43.34M$60.55M$48.08M
Total Costs & Expenses$72.19M$136.56M$282.89M$138.78M
Interest Income$0.00$0.00$0.00$187000.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$3.96M$3.90M$5.97M$4.90M
EBITDA$34.50M$20.60M$46.64M$12.90M
EBITDA Ratio$0.35$0.13$0.29$0.08
Operating Income$27.43M$16.70M$30.07M$10.73M
Operating Income Ratio$0.28$0.11$0.19$0.07
Other Income/Expenses (Net)$2.87M-$1.39M-$5.97M$80000.00
Income Before Tax$30.29M$15.31M$24.10M$14.40M
Income Before Tax Ratio$0.30$0.10$0.15$0.09
Income Tax Expense$21.23M$0.00$11.05M$3.58M
Net Income-$2.20M$15.31M$12.90M$14.40M
Net Income Ratio-$0.02$0.10$0.08$0.09
EPS-$0.03$0.19$0.16$0.18
Diluted EPS-$0.03$0.19$0.16$0.18
Weighted Avg Shares Outstanding$80.09M$80.07M$79.97M$79.97M
Weighted Avg Shares Outstanding (Diluted)$80.11M$80.07M$82.72M$79.97M

Financial performance has remained strong, with revenue growing from $153.10M in Q1 2024 to $99.62M in Q4 2024. Gross profit continued to perform well, with margins at 56% in the latest quarter. Operating income reached $27.43M in Q4 2024, holding a steady 28% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $34.50M. Net income dropped to -$2.20M, keeping EPS at -$0.03. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;